| Business Summary | | Novo-Nordisk
A/S
is
a
focused
healthcare
company.
The
Company
has
a
broad
diabetes
product
portfolio
that
includes
advanced
products
within
the
area
of
insulin
delivery
systems.
In
addition,
Novo
Nordisk
is
engaged
in
areas
such
as
coagulation
disorders,
human
growth
hormone
and
hormone
replacement
therapy.
Novo
Nordisk
manufactures
and
markets
pharmaceutical
products
and
services
that
are
designed
to
make
a
significant
difference
to
patients,
the
medical
profession
and
society.
In
early
1999,
it
was
decided
that
Novo
Nordisk
would
de-merge
into
two
main
businesses,
Healthcare
and
Enzymes.
The
de-merger
enables
the
two
businesses
to
increase
their
operational
freedom
and
focus
on
what
they
do
best.
On
November
14,
2000
Novo
Nordisk
and
Novozymes
began
operating
as
two
separate
listed
companies. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NVO
is
a
healthcare
company
that
specializes
in
products
for
the
treatment
of
diabetes,
as
well
as
products
in
the
areas
of
coagulation
disorders,
human
growth
hormone
and
hormone
replacement.
For
the
fiscal
year
ended
12/00,
revenues
rose
27%
to
DKK20.81
billion.
Net
income
according
to
U.S.
GAAP
rose
45%
to
DKK3.56
billion.
Revenues
reflect
increased
sale
of
Diabetes
care
and
Coagulation
Disorder
products.
Earnings
also
reflect
a
decrease
in
production
costs. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
6,001,000;
after
tax
earnings
were
887,000. (Preliminary; reported in thousands of Danish Krone.) | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Mads Øvlisen | Chairman | Lars Rebien Sorensen | Pres,
CEO | Jesper Brandgaard | CFO | Lars Almblom Jorgensen | COO | Mads Krogsgaard Thomsen | CSO |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|